BioHarvest Sciences Inc. announced on March 4, 2025, new in vitro test results for its proprietary Olive Cell compound, demonstrating a reduction in fat accumulation in human liver cells. This finding is significant as fat accumulation in the liver is a primary cause of non-alcohol fatty liver disease (NAFLD), which affects 30-40% of U.S. adults.
The Olive Cell compound also mitigated fat accumulation in a liver steatosis model and reduced collagen type 1 in experimental models of liver fibrosis. The company attributes these positive results to the high levels of Verbascoside, a plant-derived polyphenol with known anti-inflammatory properties, present in BioHarvest's compound.
Based on these results, BioHarvest expects to begin selling the Olive Cell product as a nutraceutical in 2026. The company also plans to explore potential partnerships with pharmaceutical companies for a different regulatory pathway, aiming to provide a next-generation therapeutic solution for liver health.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.